表紙
市場調査レポート

先発注射剤

Branded Injectables to 2020

発行 Greystone Research Associates 商品コード 300894
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
先発注射剤 Branded Injectables to 2020
出版日: 2014年05月02日 ページ情報: 英文
概要

コーティング剤・デバイス設計の進歩により、ほんの数年前には不可能だったプレフィルド生物製剤が可能になっています。プレフィルド薬剤カートリッジは、ペン型注射器・自己注射器のコストを削減し、慢性疾患のさらに大きなセグメントへのアクセスを可能にしています。

当レポートは、先発(ブランド)注射剤市場について取り上げ、主要10治療分野別の分析、設計・技術関連の問題、および今後の予測などを提供しており、概略下記の構成でお届けいたします。

調査ハイライト

  • 治療の主要10市場における治療需要の促進因子の分析・ブランド注射剤の評価
  • 設計要因、材料選択の問題、技術および市場開発問題の分析
  • ブランド注射剤市場に影響する重大なマネージドケア、技術および規制要因の評価
  • 市場データ・予測の提供

目次

  • エグゼクティブサマリー
  • 抗凝血剤
  • 抗ウィルス剤
  • 自己免疫疾患
  • 多発性硬化症
  • 糖尿病
  • 造血剤
  • ホルモン補充
  • 片頭痛
  • 骨粗しょう症
  • リプロダクティブヘルス
目次
Product Code: BRJ613F

Advances in coatings and device designs have led to prefilled biologicals in patient-friendly drug-device combination products that were not possible just a few years ago. Prefilled drug cartridges have reduced the cost of injectable pens and autoinjectors, making them accessible to a larger segment of the chronically ill. Injectors with advanced features such as variable dosing, dose counters and audible cues are making self-administration safer for patients prescribed immune modulators with black box warnings. To streamline the drug-device development process, drug developers are increasingly aligning themselves with device suppliers, increasing the level of concurrent engineering, identifying design challenges earlier and minimizing possible delays that could result. This trend represents risks for injectable drug firms competing for device solutions for their sophisticated formulations. It is also an opportunity for smaller device suppliers who are able to demonstrate the financial and technological resources to address the needs of injectable drug developers.

Convergence and Evolution in Key Markets

The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. Now this segment is evolving in response to changing patient populations, new classes of powerful therapeutic drugs and healthcare administration initiatives. A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patientfriendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

Highlights

  • Analyzes therapeutic demand drivers and evaluates branded injectables in ten major therapeutic markets
  • Analyzes design factors, material selection issues, technologies and market development issues
  • Assess significant managed care, technology, and regulatory factors affecting branded injectable drug markets.
  • Provides market data and forecasts to 2020

SAMPLE

Charts, Graphs and Tables Designed to Provide Insight and Clarify

Table of Contents

  • Executive Summary
  • Anticoagulants
  • Antivirals
  • Autoimmune Diseases
  • Multiple Sclerosis
  • Diabetes
  • Hematopoietics
  • Hormone Replacement
  • Migraine
  • Osteoporosis
  • Reproductive Health
Back to Top